Boston Scientific Corporation Pricing of Senior Notes
Boston Scientific Corporation, recognized as a leader in medical technology, has made a significant announcement regarding the pricing of €1.5 billion of senior notes. This strategic financial maneuver demonstrates the company's commitment to advancing its operations and improving healthcare solutions across the globe. The offering consists of two sets of notes: €850 million of 3.000% notes due 2031 and €650 million of 3.250% notes due 2034. Each note is expected to play a crucial role in funding the company's initiatives and maintaining its growth trajectory.
Expected Closing and Use of Proceeds
The anticipated closing for this major financial event is set for a date soon, pending standard closing conditions. Boston Scientific intends to use the proceeds from this offering in a responsible manner. Specifically, the funds will assist with the repayment of existing senior notes and support various corporate needs, including paying interest and funding potential acquisitions. These plans are in line with the company's philosophy of effective capital management.
Details of the Offering
American Medical Systems Europe B.V., a fully owned subsidiary of Boston Scientific, will guarantee the notes, offering additional assurance to investors. This public offering is a clear indication of the company's strategic approach in managing its financial landscape. Boston Scientific has always prioritized transparency and investor confidence, making this offering an integral part of its financial strategy.
About Boston Scientific
For more than 45 years, Boston Scientific has been transforming lives with its innovative medical technologies. The company focuses on improving the health of patients around the world, creating a wide array of high-performance medical solutions that address various unmet patient needs. From cardiovascular to neurological conditions, their devices help physicians effectively diagnose and treat complex health issues, ultimately aiming to reduce healthcare costs.
Commitment to Innovation
Boston Scientific’s dedication to advancing science is reflected in their ongoing development of new technologies. With a keen focus on research and development, the company strives to ensure that its products remain at the forefront of medical innovation. This commitment is crucial not only for their business growth but also for enhancing patient outcomes and experiences.
Contact Information
Those interested in learning more about Boston Scientific can reach out to its media and investor relations teams. Chanel Hastings leads the media relations at +1 (508) 382-0288. For inquiries regarding investments, Jon Monson manages investor relations and can be contacted at +1 (508) 683-5450. Both professionals are on standby to provide more information about the company’s exciting ventures.
Frequently Asked Questions
What are the terms of the new senior notes offered by Boston Scientific?
Boston Scientific is offering €850 million of 3.000% notes due in 2031 and €650 million of 3.250% notes due in 2034.
How will the proceeds from the offering be used?
The proceeds will be used for repaying existing senior notes and for general corporate purposes, including funding potential acquisitions.
Who guarantees the notes issued in this offering?
The notes will be fully and unconditionally guaranteed by Boston Scientific Corporation.
What is the significance of this pricing announcement for the company?
This pricing announcement is a key part of the company’s financial strategy and reflects its commitment to effective capital management and investor relations.
How can investors learn more about Boston Scientific's offerings?
Investors can contact Chanel Hastings for media inquiries or Jon Monson for investment-related questions directly at their provided phone numbers.
